Abion

ABION (formerly known as Abion Inc.) is a clinical-stage biopharmaceutical company headquartered in Seoul, South Korea, dedicated to the research and development of innovative new drugs targeting cancer and neurological diseases. Founded in 2007, ABION focuses on precision oncology with a pipeline of therapeutic drugs for rare and incurable diseases, including anticancer candidates such as vabametkib. The company advances its pipeline through strong partnerships with domestic and international biopharmaceutical entities, guided by four strategic R&D pillars: target-oriented approach, deep-dive research, commercial value enhancement, and proactive licensing-out. ABION is publicly listed on the KOSDAQ exchange (KRX: 203400) and is committed to sustainable, responsible research practices that improve quality of life for patients worldwide.